No Data
No Data
No Data
No Data
No Data
Institutional Owners May Take Dramatic Actions as Emergent BioSolutions Inc.'s (NYSE:EBS) Recent 16% Drop Adds to One-year Losses
Yahoo FinanceApr 17 22:44
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
cls.cnApr 15 14:37
Benchmark: Reiterates the Emergent BioSolutions (EBS.US) rating and adjusted from buy to buy, with a target price of $5.00.
Benchmark: Reiterates the Emergent BioSolutions (EBS.US) rating and adjusted from buy to buy, with a target price of $5.00.
Zhitong FinanceApr 11 21:10
Benchmark Reiterates Buy on Emergent BioSolutions, Maintains $5 Price Target
Benchmark analyst Robert Wasserman reiterates Emergent BioSolutions with a Buy and maintains $5 price target.
Analyst UpgradesApr 11 21:05
Emergent BioSolutions Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/11/2024 119.3% Benchmark → $5 Reiterates Buy → Buy 03/07/2024 119.3% Benchmark → $5 Upgrades Hold → Buy
BenzingaApr 11 21:03
Analysts' Top Healthcare Picks: Emergent Biosolutions (EBS), Vera Therapeutics (VERA)
TipRanksApr 11 19:20
No Data
No Data